Breaking News
Sort by:
Top Post
Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine
Google Cloud has announced two new AI-powered life sciences solutions to accelerate drug discovery and […]
Servier Receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo […]
BRIM Plans to launch a New Funding Round to Accelerate Late-Stage Clinical Trial and Initiate a New Phase 2 Trial for Orphan Drug BRM424
BRIM Biotechnology, a clinical-stage biotechnology company focusing on developing regenerative peptides for ophthalmology and degenerative joint […]
FDA Accepts Application for Roche’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s […]
SynCrest Launches CRDMO Service for Peptide-based Therapeutics
SynCrest, a peptide and nucleotide CRDMO (Contract Research, Development and Manufacturing Organization) joint venture between […]
Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701
Eisai announced today that it has entered into a joint development agreement with Bliss Biopharmaceutical […]
BeiGene Receives New Approvals for BRUKINSA (zanubrutinib) in China
BeiGene, a global biotechnology company, has announced the China National Medical Products Administration (NMPA) approved […]
Eli Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease
Eli Lilly and Company have announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study […]
Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors
Brenus Pharma announces two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal […]
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine, a clinical stage genome editing company, today announced that the US Food and […]
Alnylam & Regeneron Report Positive Data on ALN-APP, an Investigational Therapeutic for Alzheimer’s Disease & Cerebral Amyloid Angiopathy
Alnylam Pharmaceuticals and Regeneron Pharmaceuticals announced today positive interim results from the ongoing single ascending […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more